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ESA INITIATION
BACKGROUND
The introduction of recombinant human erythropoietin
(rHuEPO) into clinical practice in the 1980 s was a major
breakthrough in the treatment of the anemia of patients with
CKD. The development of rHuEPO was aimed at replacing
the insufficient endogenous erythropoietin (EPO) produc-
tion related to CKD progression. It remains unclear whether
the main cause of anemia is a loss of kidney EPO production
capacity or a derangement in oxygen sensing, as proposed
more recently.105
In the early years, rHuEPO administration was regarded
by the nephrology community as a beneficial therapy for
long-term dialysis patients whose Hb values fell to extremely
low levels, making them transfusion-dependent. The im-
mediate benefit of rHuEPO in CKD patients with severe
anemia and anemia-related signs and symptoms was clear. In
addition, the reduction in the need for regular blood
transfusions was another major benefit, resulting in
less frequent transmission of blood-borne viral diseases,
such as hepatitis B and C, less allosensitization, predisposing
to prolonged wait times or failure to receive a kidney
transplant, transplant rejection, and less transfusional
hemosiderosis.106–109
After introduction of rHuEPO into clinical practice its
administration was limited to dialysis patients with the most
severe forms of anemia. Progressively, its use was extended to
the majority of dialysis patients with renal anemia, and
subsequently also to anemic patients with CKD 4–5 in
countries in which the high cost of rHuEPO did not limit the
number of patients eligible for this treatment.
Hb targets also increased progressively, often into the
range of normal values. The idea that anemia should be
corrected completely was based on pathophysiologic con-
siderations and the demonstration by numerous observa-
tional studies of an inverse association between Hb
concentrations up into the normal range and intermediate
outcomes such as left ventricular hypertrophy,110 as well as
hard patient outcomes such as cardiovascular events,111–113
hospital admission,114 and death.115,116 Of note, a recent
study also showed that CKD 5D patients with naturally
occurring Hb concentrations greater than 12 g/dl (120 g/l)
were not at increased mortality risk.117 However, the
suggestion drawn from epidemiological studies that anemia
should be completely corrected in patients with CKD was not
supported by the Normal Hematocrit Study in CKD 5D
patients118 and several recent randomized controlled trials
(RCTs) performed in large CKD patient cohorts (Supple-
mentary Table 7 online).
In CKD 5D patients Hb concentrations often fall below
8 g/dl (80 g/l) if anemia is untreated, whereas in CKD ND
patients higher Hb concentrations are usual, unless patients
are close to dialysis or have another contributing cause. The
decision to prescribe ESAs should be based on evidence
accrued from RCTs. However substantial heterogeneity exists
in RCTs performed to evaluate ESA therapy, particularly in
relation to classification of patients, research design, baseline
Hb, target Hb, clinical outcome measures, and definitions of
clinically meaningful improvements.
Outcomes of interest in RCTs of ESAs include mortality,
cardiovascular and kidney endpoints, safety, quality of life
(QoL), blood transfusions and cost. QoL outcomes are
particularly important for CKD 5D patients and for some
may be more important than cardiovascular events or
mortality, since they have relatively short life expectancy
and the symptoms attributable to anemia (e.g., low energy,
fatigue, decreased physical function, and low exercise
capacity) occur frequently and can be disabling.119 However,
QoL is extremely difficult to quantify as is the clinical
importance of changes measured. Furthermore, unless
assessed under rigorous double-blind conditions, the validity
of QoL measurements is questionable. Avoidance of transfu-
sions is important, as mentioned above.
The guidelines to treat or not to treat the anemia of CKD
are also valid for CKD 4–5T patients. Of note, blood
transfusions may increase the risk of alloreactivity and
rejection episodes after kidney transplantation.120 In addition
a recent randomized trial has shown that early post-kidney
transplant anemia correction by ESAs reduces the progres-
sion of allograft nephropathy, although its effect on hard
outcomes in this patient population remains unknown.121
3.1: Address all correctable causes of anemia (including
iron deficiency and inflammatory states) prior to
initiation of ESA therapy. (Not Graded)
RATIONALE
After diagnosing anemia in a patient with CKD all correctable
causes should be treated before considering ESA therapy.
Above all, this recommendation is based on the observation
that iron supplementation given to CKD patients with
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proven iron deficiency or impaired iron availability (‘func-
tional iron deficiency’) generally leads to an increase in Hb
(See Chapter 2). However, the correction of other deficiency
states also may ameliorate anemia. In patients with
inflammatory diseases, including bacterial and viral infec-
tions, the attenuation of the inflammatory status is often
followed by an improvement of Hb.
There are several reasons why correctable causes other
than erythropoietin deficiency should be actively sought. As
in any disease state, pathological conditions which can be
cured should be corrected first. As examples, ESA treatment
is unlikely to be fully effective in raising Hb concentrations
until either severe systemic bacterial infections or severe
secondary hyperparathyroidism are appropriately treated
(Supplementary Table 8 online). When several different
factors are thought to contribute to the anemia of CKD, even
though the main underlying cause is impaired kidney EPO
synthesis, appropriate medical care dictates treating all
underlying causes.
3.2: In initiating and maintaining ESA therapy, we
recommend balancing the potential benefits of redu-
cing blood transfusions and anemia-related symptoms
against the risks of harm in individual patients (e.g.,
stroke, vascular access loss, hypertension). (1B)
RATIONALE
Treatment of severe anemia
Objective evidence to support treatment of Hb concentra-
tions below 9 g/dl (90 g/l) is quite strong because the
transfusion benefits are substantial and the QoL improve-
ments are clinically important. However the safety of ESAs in
treating severe anemia has not been evaluated in large
placebo controlled trials.
The Canadian Erythropoietin Study Group reported
a double-blind RCT of 118 CKD 5HD patients in 1990.
ESA was utilized in patients with Hb concentrations o9 g/dl
(o90 g/l), and three randomly allocated groups were
followed (placebo, target Hb 9.5–11 g/dl [95–110 g/l], high
target Hb 411 g/dl [4110 g/l]).122 Baseline Hb was 7.0 g/dl
(70 g/l) and the mean transfusion requirement was 7
transfusions per year. After 8 weeks, 58% (N¼ 23/40) in
the placebo group were transfused and only 2.5% (N¼ 1/40)
was transfused in the group with target Hb of 9.5–11g/dl
(95–110 g/l) and 2.6% (N¼ 1/38) in the group with target
Hb411g/dl (4110 g/l). After 6 months, significant improve-
ments in fatigue, physical function, and 6minute walking
tests were reported for the low Hb group compared to
placebo, but no improvement was observed comparing low vs
high Hb group. In an open-label RCT of only 83 CKD ND
patients with Hb o10 g/dl (o100 g/l), significant improve-
ments in energy and physical function were also reported.123
Treatment of moderate anemia
There are several large RCTs of ESA therapy where baseline
Hb is410 g/dl (4100 g/l). 118,124–128 The intervention being
tested in these trials is complete correction of anemia with
ESAs, compared to partial correction with ESAs in five
RCTs118,124–126,128 and to placebo in one.127 A double-blind
design is necessary to accurately assess subjective or clinician-
driven endpoints particularly QoL, starting dialysis, and
giving transfusions. Notably, only 3 of the 6 trials were
double-blind – the Normal Hematocrit Study reported in
1998,118 the Canada-Europe Study reported in 2005,126 and
TREAT reported in 2009.127 The Scandinavian Study,125
CREATE124 and CHOIR128 trials were open label.
The US Normal Hematocrit Trial by Besarab et al.118 was
the first of a series of RCTs which cast serious doubt on the
assumption that full anemia correction should be achieved in
the majority of dialysis patients. A cohort of 1233 prevalent
CKD 5HD patients with symptomatic heart failure or
ischemic heart disease were allocated to either partial
treatment of anemia or full anemia correction, using
epoetin-alfa. The eventually achieved hematocrit values were
31% and 40%, respectively. In the normal hematocrit group
treated with epoetin there were 183 deaths and 19 myocardial
infarcts, producing 202 primary events, compared to 164
events (150 deaths, 14 myocardial infarcts) in the group in
which anemia was partially corrected with epoetin. The risk
ratio for the primary endpoint was 1.3 (95% CI 0.9–1.9)
which did not satisfy the pre-specified criterion for statistical
significance (even though the nominal p value was 0.03) after
adjusting for interim analyses. The trial was stopped early in
a situation where the primary hypothesis was unlikely to be
proven and the intervention being tested caused harm: 39%
had vascular access clotting in the intervention arm and 29%
in the control arm (P¼ 0.001).
The double-blind Canada-Europe trial by Parfrey et al.126
of 596 incident CKD 5HD patients without symptomatic
heart disease (18% with diabetic nephropathy) examined the
question whether full anemia correction by epoetin-alfa in
the group randomized to a Hb target of 13.5–14.5 g/dl
(135–145 g/l), as compared to partial treatment of anemia in
the group randomized to a Hb target of 9.5–11.5 g/dl
(95–115 g/l), had a beneficial effect on left ventricular volume
and mass index. The eventually achieved Hb values were 13.1
and 10.8 g/dl (131 and 108 g/l), respectively. There was no
difference in left ventricular volume index or mass index
between the two groups during this 96-week study. Of note,
patients in the full anemia correction group had a
significantly higher stroke incidence (secondary endpoint)
than patients in the partial treatment correction group.
However, the absolute numbers of patients with stroke were
very small. As one might expect, the high Hb group received
significantly fewer transfusions than the low Hb group, but
extent of the benefit was modest: although 9% in the high Hb
arm received at least one transfusion compared to 19% in the
low Hb arm (P¼ 0.004) during the 96-week study, the
transfusions per patient per year was 0.3 in the high Hb arm
and 0.7 in the low Hb arm (Po0.0001).129 In addition
significant improvements in QoL were reported for the
a priori selected domains of vitality and of fatigue.126,130
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The goal of the CREATE study by Drueke et al.124 was to
show superiority of full anemia correction in terms of
cardiovascular events, as compared to partial correction of
anemia, when starting ESA therapy at an earlier stage than
end-stage renal disease (ESRD). In this trial, 603 CKD 3–5
patients (26% with diabetes) were randomly allocated to
either a Hb target of 13.0–15.0 g/dl (130–150 g/l) or a Hb
target of 10.5–11.5 g/dl (105–115 g/l) using epoetin-beta. The
eventually achieved Hb values were 13.5 and 11.6 g/dl (135
and 116 g/l), respectively. Dialysis was required in signifi-
cantly more patients in the high Hb group than in the low Hb
group. However the rate of fall of GFR in the two groups
during the 3 year study was similar. Statistically significant
improvements in some domains of QoL, including physical
function and vitality, were observed in the high Hb group,
although these must be interpreted cautiously because the
study was open-label.
The US CHOIR study by Singh et al.128 similarly aimed to
show superiority of full anemia correction by ESA admin-
istration in terms of cardiovascular events and death,
as compared to partial treatment of anemia, in patients
with CKD not yet on dialysis. In this trial, 1432 CKD 3–4
patients (49% with diabetes) were randomized to Hb targets
of 13.5 g/dl (135 g/l) and 11.3 g/dl (113 g/l) using epoetin-
alfa. Withdrawal rate was high: 17% due to renal replacement
therapy and 21% for other reasons. The study was
prematurely stopped after an interim analysis with a median
study duration of 16 months. The achieved Hb values
were 12.6 and 11.3 g/dl (126 and 113 g/l), respectively. At this
time point, 125 patients in the complete anemia correction
group but only 97 patients in the standard correction
group had reached the primary combined cardiovascular
endpoint (P¼ 0.03). No differences in QoL were observed
comparing the two groups although, again, this finding must
be interpreted cautiously because the study was open-label.
Finally, the international trial of darbepoetin-alfa in type 2
diabetes and CKD (TREAT) by Pfeffer et al.127 examined
cardiovascular and kidney outcomes in 4038 CKD 3–4
patients. Of note, this is by far the largest ESA trial, and
has the best research design, as it was placebo controlled and
double-blinded. Patients received either darbepoetin-alfa to
achieve a Hb target of 13.0 g/dl (130 g/l) or placebo with
rescue darbepoetin-alfa when the Hb concentration was
o9.0 g/dl (o90 g/l). The achieved Hb values were 12.5 and
10.6 g/dl (125 and 106 g/l), respectively. The median follow-
up duration of the study was 29 months. There were no
differences in the two primary endpoints, which were the
composite outcomes of death or a cardiovascular event (first
primary endpoint) and death or ESRD (second primary
endpoint). The hazard ratio for death/composite cardiovas-
cular event was 1.05 (95% CI 0.94–1.17), and for death or
ESRD it was 1.06 (95% CI 0.96–1.19). However there was a
substantial increased risk of stroke (HR 1.92; 95% CI
1.38–2.68), although the absolute risk of stroke overall was
modest: 5.0% of the high Hb group had a stroke compared to
2.6% in the placebo group (Po0.001). The relative increase
in risk of stroke was similar in patients with and without a
past history of stroke. As a result, the absolute risk of stroke
was substantial in the 11% of subjects with a prior history of
stroke; 12% in the darbepoetin group compared to 4% in the
placebo group. Venous thrombo-embolic events occurred
significantly more frequently in the high Hb arm (2.0%)
compared to the placebo arm (1.1%, P¼ 0.02). A signal that
normalization of Hb with darbepoetin may be harmful in
patients with a history of malignancy was reported following
a post-hoc analysis: 14/188 (7.4%) of those with a history of
malignancy at baseline died from cancer in the darbepoetin
arm compared to 1/160 (0.6%) (P¼ 0.002) in the placebo
arm. A statistically significant improvement in Functional
Assessment of Cancer Therapy-Fatigue (FACT-fatigue) scores
was reported at week 26 favoring the darbepoetin group, but
the clinical significance of this was modest, as 55% of the
high Hb group had a clinically important improvement in
fatigue score compared to 50% of the placebo group.
Transfusions were prescribed relatively frequently, and more
often in the placebo arm (25%) compared to the high Hb
arm (15%). The harm:benefit trade-off in TREAT was 1
stroke for 5 transfusions prevented by the high Hb target131
(Supplementary Tables 9–19 online). In a large subset of the
TREAT patients QoL was assessed using FACT-fatigue, SF-36,
and EQ-5D through 97 weeks. Compared to placebo,
darbepoetin conferred a consistent, but small improvement
over 97 weeks in fatigue and overall QoL, but none in energy
and physical function. Interim stroke had a substantial
negative impact on fatigue and physical function.132
Meta-analyses
Assessment of ESAs in CKD using meta-analysis is proble-
matic because of the heterogeneity of patients entered, the
different quality and research designs of the RCTs performed,
and differences in definitions of endpoints. In addition
abstraction of aggregate data from the reports of RCTs to
populate the meta-analysis data base is also a limitation, as
individual patient data would be preferable. The most recent
meta-analysis133 concluded that higher Hb concentrations in
CKD increases risk for stroke (relative risk [RR] 1.51, 95% CI
1.03–2.21), hypertension (RR 1.67, 95% CI 1.31–2.12), and
vascular access thrombosis (RR 1.33; 95% CI 1.16–1.53), and
may perhaps increase risk for death (RR 1.09; 95% CI
0.99–1.20), serious cardiovascular events (RR 1.15, 95% CI
0.98–1.33) or ESRD (RR 1.08; 95% CI 0.97–1.20). In our
opinion, because of the heterogeneity of patients and
interventions across studies in the meta-analysis greater
credence should be given to the results of the very large,
placebo controlled, double-blind trial, TREAT, than to the
meta-analyses, in areas where the results differ: TREAT found
no difference between the higher Hb, darbepoetin, group and
the lower Hb, placebo, group for the two primary composite
outcomes (either death or a cardiovascular event, or death or
a renal event).127
The existing meta-analyses of QoL outcomes are further
complicated by inclusion of data from open label studies,
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different instruments to measure QoL, differences in research
design across RCTs, incomplete reporting as some trials chose
(a priori) specific domains as trial outcomes, and differences
in the definition of clinically meaningful improvement in
QoL domains.119 Results from two systematic reviews
published recently134,135 suggest that improvements in QoL
are maximized in the 10–12 g/dl (100–120 g/l) range. In CKD
ND patients the review focused on energy and physical
function134 and in CKD 5D patients the review focused
on physical function and the meta-analysis on exercise
tolerance.135
3.3: We recommend using ESA therapy with great caution,
if at all, in CKD patients with active malignancy—in
particular when cure is the anticipated outcome—
(1B), a history of stroke (1B), or a history of
malignancy (2C).
RATIONALE
The joint guideline from the American Society of Clinical
Oncology136 and the American Society of Hematology137
recommend using ESA therapy with great caution in patients
with active malignancy, particularly when cure is the
anticipated outcome. This advice is supported in CKD
patients by the post-hoc analysis in TREAT which demon-
strated a significantly higher death rate from cancer
in the darbepoetin arm in patients with a history of a
malignant condition at baseline as compared with the
placebo arm.127
The relative risk of stroke in patients in the darbepoetin
arm of TREAT was the same in those with and without a
history of stroke (i.e., approximately doubled). However
the absolute risk of stroke was much higher in subjects
with a history of stroke (in both study arms) and the absolute
risk of stroke attributable to high Hb/darbepoetin was
particularly high, 8% in those with a history of stroke vs
1% in those without a history of stroke over 29 months.138
Consequently the Work Group concluded that ESAs should
be used with great caution in those with a prior history
of stroke.
3.4.1: For adult CKD ND patients with Hb concentration
Z10.0 g/dl (Z100 g/l), we suggest that ESA therapy
not be initiated. (2D)
3.4.2: For adult CKD ND patients with Hb concentration
o10.0 g/dl (o100 g/l) we suggest that the decision
whether to initiate ESA therapy be individualized
based on the rate of fall of Hb concentration, prior
response to iron therapy, the risk of needing a
transfusion, the risks related to ESA therapy and the
presence of symptoms attributable to anemia. (2C)
3.4.3: For adult CKD 5D patients, we suggest that ESA
therapy be used to avoid having the Hb concentra-
tion fall below 9.0 g/dl (90 g/l) by starting ESA
therapy when the hemoglobin is between 9.0–10.0 g/
dl (90–100 g/l). (2B)
3.4.4: Individualization of therapy is reasonable as some
patients may have improvements in quality of life at
higher Hb concentration and ESA therapy may be
started above 10.0 g/dl (100 g/l). (Not Graded)
3.4.5: For all pediatric CKD patients, we suggest that the
selection of Hb concentration at which ESA therapy
is initiated in the individual patient includes
consideration of potential benefits (e.g., improve-
ment in quality of life, school attendance/perfor-
mance, and avoidance of transfusion) and potential
harms. (2D)
RATIONALE
In adult CKD-ND patients TREAT demonstrated that the
high Hb darbepoetin arm was associated with harm. In the
patients on placebo with rescue treatment allowed when Hb
fell to below 9.0 g/dl (90 g/l) the achieved median Hb value
was as high as 10.6 g/dl (106 g/l), despite the majority of
patients receiving no or little darbepoetin127 (Supplementary
Tables 15–19 online).
There is no convincing evidence that the active increase of
Hb towards concentrations in the normal range leads to
demonstrable benefit in adult patients with CKD stages 3–5.
Moreover, when Hb falls below 10 g/dl (100 g/l) in these
patients the Work Group were unconvinced that all patients
should have an ESA initiated, particularly as the rate of Hb
fall may be slow. It was suggested that the decision to initiate
ESA therapy in CKD-ND when Hb is 49.0 and o10.0 g/dl
(490 and o100 g/l) should be individualized based on risk
of requiring transfusions and on the presence of symptoms
attributable to anemia, particularly as some patients may be
at higher risk of requiring red-cell transfusions, and some
patients are more prone to developing symptoms and signs
associated with anemia (Supplementary Tables 15–19 online).
In adult hemodialysis patients the rate of fall of Hb is
faster than in ND patients, and if untreated Hb will
frequently fall below 8 g/dl (80 g/l).122 As the risk of
transfusions is high in those HD patients whose Hb falls
below 9 g/dl (90 g/l) the Work Group suggested that ESA
therapy should be used to prevent the Hb concentration from
falling below 9.0 g/dl (90 g/l), which in practice means that
the Hb concentration at which ESA should be initiated
should be between 9.0 and 10.0 g/dl [90 and 100 g/l] (Supple-
mentary Tables 9–14 online).
However, there may be subgroups of adult CKD stage 3–5
and 5D patients in whom it may not be wise to let Hb values
descend below 10 g/dl (100 g/l), particularly in elderly
patients who are more prone to developing symptoms and
signs associated with anemia, and those who are prone to
requiring red-cell transfusions.
Moreover, physical and mental performances and QoL
may be seriously compromised in adult CKD patients with
severe anemia. RCTs supporting registration of epoetin-alfa
for the treatment of anemia in dialysis patients demonstrated
that ESA treatment of subjects with a Hb of o 10 g/dl
(o100 g/l) to a Hb target of approximately 10–12 g/dl
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(100–120 g/l) improved patient-reported physical function-
ing.134,135 The question of the Hb value above which there is
no further improvement in these parameters remains
unsolved, especially for CKD-ND patients without diabetes
and CKD-5D patients with or without diabetes.
In anemic children with CKD there are no RCTs examining
the effects of ESA administration on hard outcomes. Therefore,
any suggestion for Hb targets in this subgroup of CKD patients
has to rely on results obtained in the adult CKD patient
population and on clinical experience in the pediatric setting.
The upper and lower Hb targets are opinion-based, in keeping
with the lack of pediatric specific evidence. There are a number
of factors unique to children that make exclusive reliance on
evidence in adults inappropriate such as age-specific variation of
normal Hb concentrations as well as QoL, growth, develop-
mental, and psychological differences between children and
adults.58 Limited data suggest that children with CKD and a Hb
less than 9.9 g/dl (99 g/l) are at increased risk for mortality,139
left ventricular hypertrophy,140,141 and/or decreased exercise
capacity142 compared to those with a Hb greater than 9.9 g/dl
(99 g/l). When evaluated as a continuous variable, hematocrit
(Hct) was linked directly to measures of improved health and
physical functioning in a health based QoL questionnaire
administered to a pediatric CKD population.143
ESA MAINTENANCE THERAPY
3.5.1: In general, we suggest that ESAs not be used to
maintain Hb concentration above 11.5 g/dl (115 g/l)
in adult patients with CKD. (2C)
3.5.2: Individualization of therapy will be necessary as
some patients may have improvements in quality of
life at Hb concentration above 11.5 g/dl (115 g/l) and
will be prepared to accept the risks. (Not Graded)
RATIONALE
The suggestion to set the upper Hb target in general to values
r11.5 g/dl (r115 g/l) in adult CKD patients is based on the
interpretation of the combined results of the recent major
RCTs that there may be more harm than benefit at higher Hb
concentrations. Of note, the update of the 2006 KDOQI
anemia guideline in 2007 had already led to the recommen-
dation to limit the upper Hb target to 12 g/dl (120 g/l), not to
exceed 13 g/dl (130 g/l).51 The present suggestion not to
exceed in general a Hb limit of 11.5 g/dl (115 g/l) has been
influenced by the fact that the upper boundary of the Hb
concentration in the control group of the major ESA RCTs
usually did not exceed 11.5 g/dl (115 g/l); no data exist on the
benefits of Hb targets between 11.5 and 13.0 g/dl (115 and
130 g/l); and high Hb targets are associated with adverse
outcomes.
The Work Group recognized that some patients experi-
ence an improvement in QoL when the Hb value is above
11.5 g/dl (115 g/l). This opinion is supported by the
heterogeneity of QoL outcomes in the major RCTs: in the
double-blind Canada-Europe Study and in open label
CREATE study statistically significant improvements in some
QoL domains that may be clinically important were reported
with higher Hb values.124,126,130 In the double-blind TREAT
study the QoL benefits of higher Hb were modest127,132 and
in open label CHOIR study no benefits were observed128
(Supplementary Tables 9–19 online).
As all CKD patients in TREAT study also had type 2
diabetes, it is possible that improvements in QoL may be
more difficult to achieve in this subgroup of patients than in
those not suffering from diabetes.
An increase of Hb above 11.5 g/dl (115 g/l) towards 13 g/dl
(130 g/l) may also be justified in individual patients with a
high bleeding tendency since this results in lower transfusion
needs, as shown by 8 RCTs.133
Obviously, increasing Hb above 11.5 g/dl (115 g/l) up to
13 g/dl (130 g/l) has to be weighed against the probability of
increased harm. This perspective needs to be clearly
explained to each patient who wishes to examine the possible
benefits of more complete anemia correction.
3.6: In all adult patients, we recommend that ESAs not be
used to intentionally increase the Hb concentration
above 13 g/dl (130 g/l). (1A)
RATIONALE
The strong recommendation not to aim for Hb increases to
concentrations 413 g/dl (4130 g/l) is based on the inter-
pretation of the combined results of the recent major RCTs
showing more harm than benefit with higher Hb targets, as
compared to lower Hb targets, including increased risks for
stroke,126,127 hypertension,133 and vascular access thrombosis
(in hemodialysis patients).118 TREAT did not demonstrate
significant differences for serious cardiovascular or kidney
events comparing correction of anemia with darbepoetin to
the placebo group.127 Thus the increased risk of kidney events
reported in CREATE124 and of cardiovascular events reported
in CHOIR128 were not substantiated in the much larger
TREAT trial.127 However, a recent meta-analysis point
estimate indicated increased mortality at higher Hb target133
(Supplementary Tables 9–19 online).
An exception to the recommendation to avoid Hb
increases to concentrations 413 g/dl (4130 g/l) might
however be made for patients with comorbidities that are
normally associated with elevated Hb levels (e.g., cyanotic
heart disease).
3.7: In all pediatric CKD patients receiving ESA therapy,
we suggest that the selected Hb concentration be in
the range of 11.0 to 12.0 g/dl (110 to 120 g/l). (2D)
RATIONALE
As mentioned above, in children with CKD observational
data associates high Hb with better survival139 and/or
increased exercise capacity.142 Moreover, a recent North
American Pediatric Renal Trials and Collaborative Studies
(NAPRTCS) retrospective analysis done on pediatric CKD
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patients found an increased risk of hospitalization in children
with low Hb compared to those with normal Hb.144
However, based on recent experience with the adult CKD
patient population, caution is warranted with any extrapola-
tion from observational treatment studies to conclusions on
hard outcomes. This being said, direct extrapolation of the
results from adult trials to pediatric patients is not
appropriate given the differences in causes of CKD,
contributions of age to growth and development, and impact
of comorbidities on outcomes.
ESA DOSING
3.8.1: We recommend determining the initial ESA dose
using the patient’s Hb concentration, body weight,
and clinical circumstances. (1D)
3.8.2: We recommend that ESA dose adjustments be made
based on the patient’s Hb concentration, rate of
change in Hb concentration, current ESA dose and
clinical circumstances. (1B)
3.8.3: We suggest decreasing ESA dose in preference to
withholding ESA when a downward adjustment of
Hb concentration is needed. (2C)
3.8.4: Re-evaluate ESA dose if (Not Graded):
K The patient suffers an ESA-related adverse event
K The patient has an acute or progressive illness
that may cause ESA hyporesponsiveness (see
Recommendations 3.13.1–3.13.2)
RATIONALE
The initiation of ESA therapy, ESA dose adjustments and
rates of changes have remained similar to those outlined in
the 2006 KDOQI Anemia Guideline.50 In general, the
objective of initial ESA therapy is a rate of increase in Hb
concentrations of 1.0 to 2.0 g/dl (10 to 20 g/l) per month.
This is consistent with the findings in ESA trials of CKD-
associated anemia where the mean initial rates of Hb
concentration increase were of 0.7 to 2.5 g/dl (7 to 25 g/l)
in the first 4 weeks. However, a rise in Hb of greater than
2.0 g/dl (20 g/l) over a 4-week period should be avoided.
The rate of increase varies greatly as a function of
individual ESA responsiveness. Poor responders are more
likely to be female, to have a history of cardiovascular disease
(CVD), to have signs of iron deficiency and inflammation,
and to be overweight.145 The response also depends on initial
dose, dosing frequency, and route of administration. The
dependence on dosing frequency and route of administration
concerns epoetin-alfa, epoetin-beta, and darbepoetin but
not CERA (continuous erythropoietin receptor activator
[methoxy polyethylene glycol-epoetin-beta]). When ESAs
were introduced into clinical practice over 20 years ago,
hypertension was frequently noted in the first 3 months after
initiating therapy in severely anemic patients, and seizures in
rare instances. It is possible, although not proven, that these
events were related to a too rapid rate of increase in Hb
concentrations.
Epoetin-alfa or epoetin-beta dosing usually starts at 20 to
50 IU/kg body weight three times a week. Darbepoetin-alfa
dosing usually starts at 0.45 mg/kg body weight once weekly
by subcutaneous (SC) or IV administration, or 0.75 mg/kg
body weight once every 2 weeks by SC administration. CERA
dosing starts at 0.6 mg/kg body weight once every 2 weeks by
SC or IV administration for CKD ND and CKD 5D patients,
respectively, or 1.2 mg/kg body weight once every 4 weeks by
SC administration for CKD ND patients. Higher baseline Hb
concentrations require lower initial ESA doses, except for
CERA for which there is no initial dose change. In patients
with a history of CVD, thrombo-embolism or seizures, or in
those with high blood pressure, the initial doses should be in
the lower range. Epoetin-alfa or epoetin-beta dosage may
subsequently be increased every 4 weeks by a weekly dose of
3 20 IU/kg if the increase of Hb is not adequate. Increases
in dose should not be made more frequently than once a
month. If the Hb is increasing and approaching 11.5 g/dl
(115 g/l), the dose should be reduced by approximately 25%.
If the Hb continues to increase, doses should be temporarily
withheld until the Hb begins to decrease, at which point
therapy should be reinitiated at a dose approximately 25%
below the previous dose. Alternatively, one could simply
repeat the Hb determination again in a shorter interval (e.g.,
weekly) and interpret any further rise, in particular in light of
reticulocyte counts and their direction, before considering
holding the dose. If the Hb increases by more than 1.0 g/dl
(10 g/l) in any 2-week period, the dose should be decreased
by approximately 25%. See Recommendations 3.13.1 to
3.15.2 regarding ESA hyporesponsiveness and loss of ESA
response (Supplementary Table 20 online).
Dose adjustments may be necessary once the Hb target
range has been reached. Note that in clinical practice,
achieved Hb values may easily rise above or fall below the
optimal Hb limits. Therefore, cautious dose adaptations are
required. In general, ESA dose adjustments are made only
after the first 4 weeks after ESA initiation. The frequency of
ESA dose adjustment should be determined by the rate of
increase in Hb concentrations during initial ESA therapy, the
stability of Hb concentrations during maintenance ESA
therapy, and the frequency of Hb testing. The minimum
interval between ESA dose adjustments in the outpatient
setting generally is 2 weeks because the effect of most dose
changes will not be seen within a shorter interval. ESA doses
should be decreased, but not necessarily held, when a
downward adjustment of Hb concentration is needed.
Withholding ESA doses, particularly for long periods, may
lead to a delayed decrease in Hb concentrations to less than
target range. Such a decrease may initiate periodic cycling of
Hb concentrations at greater than and less than the target Hb
range.146 Hb variability has been found to be an independent
predictor of mortality in a large US CKD 5HD patient
population147 although this observation could not be
confirmed in a large European CKD 5HD patient cohort.148
Each time a patient with CKD is hospitalized the treating
clinician should evaluate or reevaluate the patient’s ESA
304 Kidney International Supplements (2012), 299–310
chapte r 3
requirements. Disease states such as severe infections or post-
surgery may modify the ESA responsiveness profoundly. In
case of profound anemia and markedly impaired ESA
response a red cell transfusion may be preferred to
administering ESAs or increasing ESA dose.
ESA ADMINISTRATION
3.9.1: For CKD 5HD patients and those on hemofiltration
or hemodiafiltration therapy, we suggest either
intravenous or subcutaneous administration of
ESA. (2C)
3.9.2: For CKD ND and CKD 5PD patients, we suggest
subcutaneous administration of ESA. (2C)
RATIONALE
As outlined in the 2006 KDOQI guideline,50 the route of
administration should be determined by the CKD stage,
treatment setting, efficacy considerations, and the class of
ESA used. Among CKD 5D patients undergoing intermittent
hemodialysis or hemofiltration therapy, either SC or IV
administration is possible. In the outpatient setting, SC
administration is the only routinely feasible route of
administration for patients with CKD 3–5 or on peritoneal
dialysis treatment. Among short-acting ESAs, efficacy of SC
administration in patients with CKD 5HD may be superior
to that of IV administration, as shown by a large multicenter
RCT in hemodialysis patients.149 However, another RCT of
much smaller sample size did not find an advantage of SC
over IV administration in CKD 5HD patients.150 Among
long-acting ESAs, efficacy of SC compared with IV admin-
istration appears to be equivalent at examined dosing
frequencies.151–153 Furthermore, CKD 5HD patients in
general prefer IV to SC administration of ESAs because SC
administration may be painful (Supplementary Tables 21–24
online).
Frequency of administration
3.10: We suggest determining the frequency of ESA
administration based on CKD stage, treatment
setting, efficacy considerations, patient tolerance
and preference, and type of ESA. (2C)
RATIONALE
The frequency of ESA administration depends on considera-
tions of efficacy, convenience and comfort. Maximum
efficacy occurs within dosing intervals that are ESA class
specific. For example, in patients on hemodialysis treatment
receiving SC or IV short-acting ESA therapy, epoetin-alfa
efficacy decreases when the dosing is extended from 3 times
weekly to once-weekly administration,154 and even more so
when the dosing intervals are extended to every other week
administration.155 Among long-acting ESAs, darbepoetin-
alfa appears to have maximum efficacy when administered
every 2 weeks, and methoxy polyethylene glycol-epoetin-beta
(CERA) every 4 weeks.156 When converting short-acting
ESAs to long-acting ESAs, differences in drug half-life need to
be considered. For the sake of comparison, 3 times weekly
administered epoetin-alfa to darbepoetin-alfa given only
once monthly resulted in a decreased frequency of injections
needed to maintain Hb concentrations of CKD patients
within an accepted target range157 (Supplementary Tables
25–28 online).
When converting a patient from one ESA to another the
pharmacokinetic and pharmacodynamic characteristics of
the new ESA need to be taken into consideration. The
manufacturers have provided conversions from epoetin-
alfa or epoetin-beta to darbepoetin-alfa or CERA. Note that
the conversion ratios from epoetin to darbepoetin are
non-linear.
When using different types of approved ESAs (biosimilars
that have received approval by official regulatory bodies such
as FDA and European Medicines Agency [EMA]), license
information provided by companies should also be taken into
account.
TYPE OF ESA
3.11.1: We recommend choosing an ESA based on the
balance of pharmacodynamics, safety information,
clinical outcome data, costs, and availability. (1D)
3.11.2: We suggest using only ESAs that have been
approved by an independent regulatory agency.
Specifically for ‘copy’ versions of ESAs, true
biosimilar products should be used. (2D)
RATIONALE
As outlined above, the choice of short-acting or long-acting
ESAs needs to take into account a number of different aspects,
encompassing patient-oriented issues and country-specific
considerations. At present, there is no evidence that any given
ESA brand is superior to another in terms of patient
outcomes, with the historical exception of the temporary
increase in the incidence of antibody-mediated pure red cell
aplasia (PRCA) about 10–20 years ago, which was associated
with SC administration of an epoetin-alfa formulation
available in Europe, but not in the United States.158,159 It is
the considered opinion of the Work Group that the likelihood
of differences in clinical outcomes among ESA brands is low,
although there is no robust evidence supporting this
assumption (Supplementary Tables 29–32 online).
At present, a number of different types of short-acting or
long-acting ESAs are available worldwide, including original
formulations, biosimilars, and ‘copy’ ESAs which have not
been exposed to the rigor of scientific evaluation as mandated
by the regulatory agencies prior to approval. Their accessi-
bility and costs vary from country to country. True
biosimilars, as defined by the EMA, are not identical to the
originator products, but they have undergone a minimum
number of regulatory ‘equivalence’ or ‘non-inferiority’
studies to gain marketing authorization in Europe. In other
countries outside Europe, some ‘copy’ ESA products have
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been marketed that may not have undergone the same
rigorous testing.160 Since patient safety is one of the most
important drug treatment issues, only biosimilars approved
by an independent regulatory agency should be used.
EVALUATING AND CORRECTING PERSISTENT
FAILURE TO REACH OR MAINTAIN INTENDED
HEMOGLOBIN CONCENTRATION
Frequency of monitoring
3.12.1: During the initiation phase of ESA therapy,
measure Hb concentration at least monthly. (Not
Graded)
3.12.2: For CKD ND patients, during the maintenance
phase of ESA therapy measure Hb concentration at
least every 3 months. (Not Graded)
3.12.3: For CKD 5D patients, during the maintenance
phase of ESA therapy measure Hb concentration at
least monthly. (Not Graded)
RATIONALE
ESA initiation phase. The suggestion to monitor Hb values
at least monthly in patients in whom ESA therapy is started is
intended to provide sufficient surveillance information to
assist in achieving and maintaining desired Hb concentra-
tions safely and follows common practice.50 The minimum
interval between ESA dose adjustments is 2 weeks because the
effect of most dose changes will not be seen within a shorter
interval. Consideration of an ESA dose adjustment is based
on the next projected Hb concentration. Because the accuracy
of projection (extrapolation) increases with the number of
contributing data points, the frequency of Hb monitoring is
likely to be an important determinant of the accuracy of ESA
dose adjustment. However, evidence to support this line of
reasoning is indirect. Several RCTs have randomized CKD
5HD patients with target-range Hb concentrations to a
change in frequency of ESA administration, a change in ESA
class, or both. RCTs that have monitored Hb values weekly
and adjusted ESA doses as frequently as every 2 weeks have
achieved stable Hb concentrations early after randomiza-
tion.152,161,162 In contrast, an RCT that monitored Hb
concentrations and considered ESA dose adjustment monthly
required 6 to 9 months to stabilize Hb concentrations after
randomization,163 but mean Hb concentration remained
within the target range for that trial.
ESA maintenance phase. Within the recommended ranges
for monitoring and dose adjustment, unstable Hb concen-
tration, inappropriate high or low Hb concentration, and
hemodialysis favor shorter intervals of ESA administration,
whereas stable Hb concentration, within target Hb concen-
tration, peritoneal dialysis, CKD 3–5, and minimizing
laboratory resource utilization favor longer intervals for
long-acting ESAs such as darbepoetin. The frequency of ESA
dose adjustment is unaffected by length of action: during an
8-week period with weekly Hb monitoring, about equal
numbers of patients receiving either short-acting ESA thrice
weekly or darbepoetin once weekly required dose adjust-
ments (44% and 49%, respectively).162
Initial ESA hyporesponsiveness
3.13.1: Classify patients as having ESA hyporesponsiveness
if they have no increase in Hb concentration from
baseline after the first month of ESA treatment on
appropriate weight-based dosing. (Not Graded)
3.13.2: In patients with ESA hyporesponsiveness, we
suggest avoiding repeated escalations in ESA dose
beyond double the initial weight-based dose. (2D)
Subsequent ESA hyporesponsiveness
3.14.1: Classify patients as having acquired ESA hypor-
esponsiveness if after treatment with stable doses
of ESA, they require 2 increases in ESA doses up to
50% beyond the dose at which they had been stable
in an effort to maintain a stable Hb concentration.
(Not Graded)
3.14.2: In patients with acquired ESA hyporesponsiveness,
we suggest avoiding repeated escalations in ESA
dose beyond double the dose at which they had
been stable. (2D)
Management of poor ESA responsiveness
3.15.1: Evaluate patients with either initial or acquired
ESA hyporesponsiveness and treat for specific
causes of poor ESA response. (Not Graded)
3.15.2: For patients who remain hyporesponsive despite
correcting treatable causes, we suggest individuali-
zation of therapy, accounting for relative risks and
benefits of (2D):
K decline in Hb concentration
K continuing ESA, if needed to maintain Hb
concentration, with due consideration of the
doses required, and
K blood transfusions
RATIONALE
Relative resistance to the effect of ESAs is a common problem
in managing the anemia of patients with CKD and remains
the subject of intense interest, all the more since ESA
hyporesponsiveness has been found to be among the most
powerful predictors of the risk of cardiovascular events and
mortality.164 Recently a report from TREAT assessed the
initial Hb response to darbepoetin after two weight-based
doses at 2 weekly intervals, in 1872 patients with CKD and
diabetes.145 Patients with a poor response, (the lowest
quartile, who had o2% change in Hb concentration after
1 month), had higher rates of the composite cardiovascular
events (adjusted HR 1.31, 95% CI 1.09–1.59), compared to
those with a better response. Although this differential effect
may be related to comorbidity in hyporesponsive patients,
nonetheless it is possible that the high ESA doses used in
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hyporesponsive patients may be toxic. Though not empiri-
cally tested, per se, the definition of initial hyporesponsive-
ness agreed upon by the Work Group is derived from the
secondary analysis of the TREAT study.145 Since a o2%
increase in the Hb concentration is likely to be within the
variability range of Hb values in individual patients, this
value is considered as 00no increase.00 The definition of initial
hyporesponsiveness relies on presently accepted ESA starting
doses, as indicated in the Rationale under 3.8.1–3.8.4. Of
note, weight-based doses for darbepoetin do not differ for IV
or SC routes, but do differ for epoetin-alfa.
If lower initial dosages than those used in TREAT are
chosen, the diagnosis of hyporesponsiveness must take this
into account. For example, in the USA the label for
darbepoetin now recommends a starting dose of 0.45 mg
per kg per four weeks, much lower than the dose used in
TREAT or in Europe (i.e., 0.45 mg per kg per week or 0.75 mg
per kg per two weeks). If such lower starting doses are used,
repeated escalations in ESA dose should be allowed to reach
double the weight-based dose used in TREAT.
Although the distinction between initial ESA hyporespon-
siveness and acquired partial or complete loss of ESA
responsiveness in a patient with already treated, stable
anemia is somewhat artificial, it is useful in our opinion
for clinical practice.
In the Normal Hematocrit Study both the high Hb and the
low Hb groups revealed an inverse relationship between
achieved Hb and the primary outcome (death or myocardial
infarction).118 This is consistent with the idea that those
patients who failed to achieve the target Hb were unable to do
so because comorbid condition(s) existed that prevented
achievement of this target. Thus, hyporesponsiveness may just
have been a marker for adverse outcomes, although the
possibility that high ESA doses used in hyporesponsive
patients are toxic in themselves cannot be excluded. Dose-
targeting bias has been reported by the Kidney Disease Clinical
Studies Initiative Hemodialysis Study (HEMO) investiga-
tors.165 In this RCT ESRD patients, randomly allocated to
either high or low quantity of dialysis, as measured by Kt/V,
demonstrated an inverse relationship between achieved Kt/V
and mortality. The interpretation was that patients with
comorbid conditions were unable to achieve higher Kt/V and
that comorbidity predisposed these patients to earlier death.
The same principle as used with defining hyporespon-
siveness to darbepoetin could be applied to the early response
to other short-acting ESAs but cannot be applied to longer
acting ESAs such as CERA. In that case, evaluating the Hb
response after a time period of 2 months appears to be
appropriate. Early ESA hyporesponsiveness or the subsequent
occurrence of hyporesponsiveness in CKD patients with
previously stable Hb values should lead to an intensive search
for potentially correctable factors which might be causally
involved. Unfortunately, besides iron deficiency, there are
only few other easily reversible factors that contribute to ESA
hyporesponsiveness, as shown in Table 3. If other such factors
are identified they should be treated as well. Although most
disorders associated with hyporesponsiveness are readily
apparent, hyporesponsive patients should be evaluated for
coexisting oncological or hematologic disorders. They
include hematological and non-hematological malignancies
as well as such diverse hematological conditions as thalasse-
mia, sickle cell disease or the anemia associated with other
chronic diseases. Myelodysplastic syndromes are a particular
case. If at all ESA responsive, the anemia in patients with
myelodysplastic syndrome responds more slowly. Therefore,
1 month may be too short to define hyporesponsiveness in
this and several other conditions. Moreover, patients with
myelodysplastic syndromes may need higher ESA doses.
Finally, a rare disorder, PRCA, deserves special consideration
(see 3.17.1–3.17.3). The estimation of loss of ESA response
also may require a longer observation time in some patients.
Note that poor ESA response, either in the initial correction
phase or subsequently, is most often a transient condition.
Complete loss of response is exceptional. Poor responders
should periodically be re-tested for responsiveness, including
after the correction of treatable causes of hyporesponsiveness.
It is important to note that the dosing requirements may
differ substantially between children and adults. Registry data
from NAPRTCS showed that young children require higher
doses of ESA than adults, ranging from 275 U/kg/week to
350 U/kg/week for infants and 200–250 U/kg/week for older
children.166 Another retrospective analysis among patients on
chronic hemodialysis found that children and adolescents
required higher absolute doses of ESA than adults to maintain
target hemoglobin levels, despite the lower mean body weight
of the children.167 Unfortunately, there are no RCTs that
establish the appropriate dosing of ESA in children. Future
research to establish pediatric ESA dosing guidelines is needed,
especially for infants and younger children.
There may be toxicity from high doses of ESA, as
suggested, though not proven, by recent post-hoc analyses
of major ESA RCTs,145,168 especially in conjunction with the
achievement of high Hb levels.169 Therefore, in general ESA
dose escalation should be avoided. The Work Group
suggestions for initial and acquired hyopresponsiveness imply
that maximal doses should be no greater than four times
initial weight-based appropriate doses.
Table 3 | Potentially correctable versus non correctable
factors involved in the anemia of CKD, in addition to ESA
deficiency
Easily correctable Potentially correctable Impossible to correct
Absolute iron deficiency
Vitamin B12/folate
deficiency
Hypothyroidism
ACEi/ARB
Non-adherence
Infection/
inflammation
Underdialysis
Hemolysis
Bleeding
Hyperparathyroidism
PRCA
Malignancy
Malnutrition
Hemoglobinopathies
Bone marrow
disorders
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker;
PRCA, pure red cell aplasia.
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In practice, Tables 3 and 4 can guide to diagnose and
correct ESA hyporesponsiveness. In patients in whom all
correctable causes have been maximally treated but who
remain hyporesponsive, ESA therapy may be continued
cautiously at doses up to 4 times the initial dose to prevent a
further decline in Hb concentration. Red cell transfusions can
be used to prevent or treat anemia-related symptoms and
signs. The treatment strategy needs to take into account each
patient’s anemia tolerance and potential benefits and risks
linked to increases in Hb values solely obtained by high ESA
dosing.
Given the disproportionate burden of morbidity and
mortality that the hyporesponsive patient population bears
and the ESA expense that hyporesponsiveness engenders,
further research is necessary on the causes and management
of hyporesponsiveness.
ADJUVANT THERAPIES
3.16.1: We recommend not using androgens as an adjuvant
to ESA treatment. (1B)
3.16.2: We suggest not using adjuvants to ESA treatment
including vitamin C, vitamin D, vitamin E, folic
acid, L-carnitine, and pentoxifylline. (2D)
RATIONALE
Several adjuvant treatments have been proposed, either with
the goal of limiting the use of more expensive ESA therapy or
to improve ESA responsiveness.
Androgens. The use of androgens for treatment of anemia
was suggested long before rHuEPO became available in
clinical practice. Androgens were used regularly in many
centers in the treatment of anemia in dialysis patients
despite the need for intramuscular (IM) injection and a
variety of adverse events, including acne, virilization,
priapism, liver dysfunction, injection-site pain, and risk for
peliosis hepatis and hepatocellular carcinoma. The three
RCTs that tested androgens in combination with ESA therapy
in CKD 5HD patients were all small short-term studies.
Currently recommended Hb concentrations were not
achieved, and in two of them the ESA doses used were lower
than current practice.170–172 The studies did not enroll
patients with ESA hyporesponsiveness, so the effect of
androgens on hyporesponsiveness is unknown. The risks of
androgen therapy and their uncertain benefit on Hb
concentration or clinical outcomes argue against their use
as an ESA adjuvant.
Vitamin C. Vitamin C has been reported to increase the
release of iron from ferritin and the reticuloendothelial
system and increase iron utilization during heme synth-
esis.173,174 A recent meta-analysis of vitamin C use in CKD
5HD175 and a more recent small RCT176 concluded that
vitamin C may result in larger increases in Hb and may limit
the use of ESAs. In seven trials, patients generally had
functional iron deficiency and in three studies they had EPO
hyporesponsiveness (variously defined).176–178 However, the
number of patients studied was insufficient to address the
safety of this intervention. Thus the long-term safety of IV
ascorbic acid in HD patients remains undefined, and whether
secondary oxalosis should be a concern.
Convincing data do not exist for other potential adjuvants
including vitamin D, vitamin E, folic acid, L-carnitine and
pentoxifylline. Several anecdotal reports, small case series,
and nonrandomized studies, primarily in CKD 5HD patients,
have been published, but do not provide sufficient evidence
upon which to base a recommendation. Future RCTs are
clearly needed for ESA adjuvants.
EVALUATION FOR PURE RED CELL APLASIA (PRCA)
3.17.1: Investigate for possible antibody-mediated PRCA
when a patient receiving ESA therapy for
more than 8 weeks develops the following (Not
Graded):
K Sudden rapid decrease in Hb concentration at
the rate of 0.5 to 1.0 g/dl (5 to 10 g/l) per week
OR requirement of transfusions at the rate of
approximately 1 to 2 per week, AND
K Normal platelet and white cell counts, AND
K Absolute reticulocyte count less than 10,000/ml
3.17.2: We recommend that ESA therapy be stopped in
patients who develop antibody-mediated PRCA.
(1A)
3.17.3: We recommend peginesatide be used to treat
patients with antibody-mediated PRCA. (1B)
RATIONALE
Rarely, patients undergoing ESA therapy develop antibodies
that neutralize both ESA and endogenous erythropoietin.
The resulting syndrome, antibody-mediated PRCA, is
characterized by the sudden development of severe transfu-
sion-dependent anemia. Rapid recognition, appropriate
Table 4 | Practical approach in presence of ESA
hyporesponsiveness
Tests Finding and action
1. Check adherence If poor, attempt to improve (if self-injection)
2. Reticulocyte count If 4130,000/ml, look for blood loss or
hemolysis: endoscopy, colonoscopy,
hemolysis screen
Serum vitamin B12,
folate
If low, replenish
Iron status If low, replenish iron
Serum PTH If elevated, manage hyperparathyroidism
Serum CRP If elevated, check for and treat infection or
inflammation
Underdialysis If underdialyzed, improve dialysis efficiency
ACEi/ARB use If yes, consider reducing dose or
discontinuing drug
3. Bone marrow biopsy Manage condition diagnosed e.g., dyscrasia,
infiltration, fibrosis
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker;
CRP, C-reactive protein; PTH, parathyroid hormone.
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evaluation, and prompt intervention can be effective in
limiting the consequences of this life-threatening condition.
Antibody-mediated PRCA, although rare in patients admi-
nistered ESAs, received urgent attention after 1998. Between
1989 and 1998, three reports described the development of
PRCA in only a small number of patients with CKD
administered ESAs. Reports of PRCA increased sharply in
1998 and reached a peak in 2002.159,179 These reports were
associated with SC administration of an epoetin-alfa
formulation not available in the United States. After removal
of this formulation from the market, by 2004, the incidence
of new antibody-mediated PRCA had decreased to pre-1998
levels. Isolated cases of PRCA have been observed in
association with the use of other ESAs.159,179,180 Outside this
historical episode the incidence rate of PRCA with SC use of
all other forms of SC-administered ESA is estimated to be 0.5
cases/10,000 patient-years.158 Antibody-associated PRCA
stemming from IV administration of ESAs is rare and has
only been reported anecdotally.181
Recommendations based on expert opinions have been
published to guide the workup and therapy of patients
suspected to have antibody-mediated PRCA.179,182–184 The
two main distinguishing features of antibody-mediated
PRCA are the associated decline in blood Hb concentration
of approximately 4 g/dl (40 g/l) per month, and a decrease in
the number of circulating reticulocytes to o10,000/ml of
blood.185 Bone marrow biopsy characteristically shows
reduced numbers or absence of erythroblasts. The definitive
diagnosis is dependent upon demonstration of the presence
of neutralizing antibodies against erythropoietin. Evidence
for parvovirus infection as an alternative cause of PRCA
should be sought and excluded.
Following a diagnosis of antibody-mediated PRCA,
patients should stop treatment with the incriminated ESA
immediately and not resume treatment with the same or
another EPO-derived ESA.184 Immunosuppressive therapy
may hasten the disappearance of circulating antibodies in
patients with EPO-induced PRCA, and allow endogenous
erythropoiesis to recover to pre-treatment levels. In a
retrospective study of 47 patients who developed PRCA
during EPO therapy (primarily epoetin brand ‘Eprexs’ in
Europe), 29 of 37 patients (78%) who received immunosup-
pressive therapy recovered, whereas none of the nine patients
who did not receive immunosuppressive therapy recov-
ered.185 Red cell production recovered only when patients
received immunosuppressive treatment. Re-exposure to
epoetins or darbepoetin-alfa can re-induce the formation of
antibodies.186 Anaphylactoid reactions after repeated injec-
tions of epoetin- or darbepoetin-alfa have been reported in a
patient with pure red-cell aplasia.187 A novel approach to the
treatment of this condition using a synthetic, peptide-based
erythropoietin-receptor agonist (peginesatide) has generated
optimistic results,188 and has the advantage of avoiding
immunosuppressive therapy.
The recognition of antibody-mediated PRCA in patients
treated with recombinant epoetins has underscored the need
for full clinical documentation and post-marketing surveil-
lance with newer ESAs and biosimilar products, as well as
therapeutic recombinant proteins in general.189
If a decision to treat with peginesatide is taken, it
can be initiated at a dose of 0.05 to 0.075mg/kg body weight
by subcutaneous injection every 4 weeks. Subsequently,
the dose needs to be adjusted to reach the desired target
Hb value.
RESEARCH RECOMMENDATIONS
The following research questions have arisen during the
deliberations of the Work Group, and further research will be
necessary to answer them.
K In cohort studies moderate anemia is associated with an
increased incidence of cardiovascular events. Is anemia
really a risk factor for these events or is it a marker for
some other cardiovascular risk factor(s)?
K There is uncertainty about optimal Hb targets for ESA
therapy. What is the risk-benefit ratio of low Hb targets
o10.0 g/dl (o100 g/l) or high targets of 11.5–13.0 g/dl
(115–130 g/l), compared to conventional targets of
10.0–11.5 g/dl (100–115 g/l)?
K These guidelines have stressed individualization of
anemia therapy. Should the objective of anemia therapy
be improvement in clinical outcomes (provided Hb
concentration is o13.0 g/dl [o130 g/l]) rather than
achievement of a specified Hb target range? Should these
outcomes include improvements in QoL, and if so, what
defines clinically important improvements?
K As the relationship between ESA responsiveness and
hard patient outcomes may be the result of co-morbidity
or of high ESA dose, what is the impact of high vs low
dose on clinical outcomes in ESA hyporesponsive
patients?
K Is the risk-benefit ratio of anemia correction similar in
non-diabetic and diabetic CKD patients?
K Is there a difference in adverse clinical outcomes com-
paring IV and SC routes of administration?
K Are the risk-benefit ratios for biosimilars comparable to
current ESAs?
K What is the pathogenesis of cerebrovascular and vascular
toxicity associated with normalization of Hb using ESAs?
K Are CKD patients with cancer or a cancer history who are
receiving ESA therapy at higher cardiovascular risk than
non-CKD patients with cancer or a cancer history?
K What is the effect of vitamin C administration in
functional iron deficiency and what is the clinical impact
of increased oxalate levels?
K There appears to be differences in anemia treatment
outcomes between different geographic regions. What are
the reasons for this?
K What are the risks and benefits of ESA administration on
outcomes in anemic children with CKD?
K What are the appropriate, weight-based, dosing regimens
for the younger pediatric patients, especially those under
the age of two years?
Kidney International Supplements (2012) 2, 299–310 309
chapte r 3
DISCLAIMER
While every effort is made by the publishers, editorial board,
and ISN to see that no inaccurate or misleading data, opinion
or statement appears in this Journal, they wish to make it clear
that the data and opinions appearing in the articles and
advertisements herein are the responsibility of the contributor,
copyright holder, or advertiser concerned. Accordingly, the
publishers and the ISN, the editorial board and their respective
employers, office and agents accept no liability whatsoever for
the consequences of any such inaccurate or misleading data,
opinion or statement. While every effort is made to ensure that
drug doses and other quantities are presented accurately,
readers are advised that new methods and techniques
involving drug usage, and described within this Journal,
should only be followed in conjunction with the drug
manufacturer’s own published literature.
SUPPLEMENTARY MATERIAL
Supplemental Table 7: Association between anemia severity (prior to
erythropoietin use) and clinical outcome in multivariable analyses.
Supplemental Table 8: Association between hyperparathyroidism and
ESA responsiveness in multivariable analyses.
Supplemental Table 9: Evidence profile of RCTs comparing higher vs.
lower Hb targets/ESA doses in the HD-CKD and PD-CKD populations.
Supplemental Table 10: Summary table of RCTs comparing different
Hb targets/ESA doses on key clinical outcomes in the HD-CKD and
PD-CKD populations.
Supplemental Table 11: Summary table of RCTs comparing different
Hb targets/ESA doses on quality of life in the HD-CKD and PD-CKD
populations.
Supplemental Table 12: Summary table of RCTs comparing different
Hb targets/ESA doses on Fatigue, Vitality/Energy, and Physical
function in the HD-CKD and PD-CKD populations.
Supplemental Table 13: Summary table of RCTs comparing different
Hb targets/ESA doses on non-CVD/mortality adverse event rates in
the HD-CKD and PD-CKD populations.
Supplemental Table 14: Summary table of RCTs comparing different
Hb targets/ESA doses on exercise capacity in the HD-CKD and
PD-CKD populations.
Supplemental Table 15: Evidence profile of RCTs comparing different
higher vs. lower Hb targets/ESA doses in the ND-CKD populations.
Supplemental Table 16: Summary table of RCTs comparing different
Hb targets/ESA doses on key clinical outcomes in the ND-CKD
population.
Supplemental Table 17: Summary table of RCTs comparing
different Hb targets/ESA doses on quality of life in the ND-CKD
population.
Supplemental Table 18: Summary table of RCTs comparing different
Hb targets/ESA doses on Fatigue, Vitality/Energy, and Physical
function in the ND-CKD population.
Supplemental Table 19: Summary table of RCTs comparing different
Hb targets/ESA doses on non-CVD/mortality adverse event rates in
the ND-CKD population.
Supplemental Table 20: ESA protocols from the major trials in CKD
populations.
Supplemental Table 21: Evidence profile of RCTs examining IV vs. SC
EPO in CKD patients with anemia.
Supplemental Table 22: Summary table of RCTs examining IV vs. SC
ESA in CKD patients with anemia (categorical outcomes).
Supplemental Table 23: Summary table of RCTs examining IV vs. SC
ESA in CKD patients with anemia (continuous outcomes).
Supplemental Table 24: Summary table of adverse events in RCTs
examining IV vs. SC EPO in CKD patients with anemia.
Supplemental Table 25: Evidence profile of RCTs examining different
dosing schedules in CKD patients with anemia.
Supplemental Table 26: Summary table of RCTs examining different
dosing schedules in CKD patients with anemia (categorical out-
comes).
Supplemental Table 27: Summary table of RCTs examining different
dosing schedules in CKD patients with anemia (continuous out-
comes).
Supplemental Table 28: Summary table of adverse events in
RCTs examining different dosing schedules in CKD patients with
anemia.
Supplemental Table 29: Evidence profile of RCTs examining ESA vs.
ESA in CKD patients with anemia.
Supplemental Table 30: Summary table of RCTs examining ESA vs. ESA
in CKD patients with anemia (categorical outcomes).
Supplemental Table 31: Summary table of RCTs examining ESA vs. ESA
in CKD patients with anemia (continuous outcomes).
Supplemental Table 32: Summary table of adverse events in RCTs
examining ESA vs. ESA in CKD patients with anemia (categorical
outcomes).
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/anemia.php
310 Kidney International Supplements (2012), 299–310
chapte r 3
